Article
Evaluating whether KRAS/BRAF mutation status, anaemia and obstruction are associated with recurrence and mortality in non-metastatic colorectal cancer.
ANZ journal of surgery - 1 Oct 2023
Juszczyk Karolina, Afzal Mohamed Zaafer, Ganguly Timothy, Kelly Thu-Lan, Zeelie Robyn, Murphy Elizabeth Mary Ann
Abstract excerpt
BACKGROUND: KRAS and BRAF testing is currently recommended in metastatic colorectal cancer. There is evidence that KRAS and BRAF mutation status may act as a prognostic biomarker in patients with non-metastatic colorectal cancer. Data is limited on whether KRAS and BRAF mutation status impacts recurrence and mortality in patients with non-metastatic colorectal cancer. METHODS: A retrospective cohort study was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
